HBAI 20

Drug Profile

HBAI 20

Alternative Names: HBAI 20 - CyTuVax; HBAI-20

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CyTuVax
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 21 Sep 2017 Phase-II clinical trials in Hepatitis B prevention (Prevention) in Netherlands (IM) (EudraCT2016-002720-91)
  • 19 Apr 2017 Additional immunogenicity and adverse events data from a phase I trial in Hepatitis B prevention presented at the International Liver Congress 2017 (ILC-2017)
  • 29 Apr 2016 Interim immunogenicity and adverse events data from a phase I trial in Hepatitis B prevention released by CyTuVax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top